MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vhri.2026.101665

Медицинская библиотека · Value in health regional issues · 2026

Cost-Effectiveness of Vaccine for the Prevention of Herpes Zoster in Kidney Transplant Recipients in Thailand.

Dhippayom Teerapon, Dilokthornsakul Piyameth, Cho Jeong-Yeon, Bruminhent Jackrapong, Leachman Sancy A, Chaiyakunapruk Nathorn

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

Herpes zoster (HZ) poses a serious risk to immunocompromised populations, including kidney transplant recipients. Live-attenuated zoster vaccine (ZVL) or recombinant zoster vaccine (RZV) may reduce this burden. This study aimed to evaluate the cost-effectiveness of ZVL and RZV in kidney transplant patients in Thailand.

METHODS

A Markov model was developed from a societal perspective comparing no vaccination, ZVL, and RZV. Input was derived from a literature review and local data. Thai-specific costs were used with the year 2023 value. All costs and quality-adjusted life-years (QALYs) were discounted at a rate of 3%. Incremental cost-effectiveness ratios (ICERs) were calculated against Thailand's willingness-to-pay (WTP) threshold of US$4576 (B 160,000)/QALY. Sensitivity analyses were conducted. Cost-effectiveness acceptability curve was generated to calculate the probability of cost-effectiveness at varying WTP thresholds.

RESULTS

In the base-case analysis, the ICERs for ZVL and RZV were US$4652 (B 162 673) and US$126 962 (THB4 439 220)/QALY, respectively. However, if RZV's unit cost were reduced by 93%, its ICER compared with no vaccine would decrease to US$4380/QALY (B 153 138/QALY). The most influential parameters on the ICER were hospitalization length of stay, HZ incidence, and vaccine efficacy. At a WTP of US$4576 (B 160 000), ZVL had a 45.79% probability of being cost-effective, whereas RZV had a 0.00% probability.

CONCLUSIONS

ZVL was not cost-effective but close to being cost-effective based on the Thai WTP threshold, although its use is limited in immunocompromised patients. RZV offers high efficacy, but its cost-effectiveness is currently suboptimal. These findings support tailored vaccination strategies for high-risk groups in resource-limited settings.

Для цитирования: Dhippayom Teerapon, Dilokthornsakul Piyameth, Cho Jeong-Yeon, Bruminhent Jackrapong, Leachman Sancy A, Chaiyakunapruk Nathorn. Cost-Effectiveness of Vaccine for the Prevention of Herpes Zoster in Kidney Transplant Recipients in Thailand.. Value in health regional issues. 2026. DOI: 10.1016/j.vhri.2026.101665.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.